CD274 and bladder transitional cell carcinoma: To test the first hypothesis, we compared the expression profiles of human inflamed and excluded tumors from the IMVigor210 trial (348 patients with advanced-stage urothelial bladder cancer treated with atezolizumab (anti-PD-L1))8.